LC28 0126

Drug Profile

LC28 0126

Alternative Names: LC-280126; NecroX-7

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem; LG Life Sciences
  • Class Antifibrotics; Cardiovascular therapies; Hepatoprotectants; Indoles; Small molecules; Thiazoles
  • Mechanism of Action NF-kappa B inhibitors; NFATC-transcription-factor-inhibitors; Proto oncogene proteins c fos inhibitors; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatic fibrosis

Highest Development Phases

  • Phase II Myocardial infarction
  • Preclinical Pulmonary fibrosis
  • No development reported Hepatic fibrosis

Most Recent Events

  • 15 Nov 2017 LG Life Sciences completes a phase I trial in Healthy volunteers in South Korea (NCT03196804)
  • 07 Jun 2017 LG Life Sciences initiates enrolment in a phase I trial in Healthy volunteers in South Korea (NCT03196804)
  • 03 Sep 2016 Preclinical trials in Pulmonary fibrosis in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top